Cargando…

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Young-Hwan, Lee, Heirim, Kim, Do Young, Lee, Hye Won, Yu, Su Jong, Cho, Young Youn, Jang, Jeong Won, Jang, Byoung Kuk, Kim, Chang Wook, Kim, Hee Yeon, Park, Hana, Cho, Hyo Jung, Park, Bumhee, Kim, Soon Sun, Cheong, Jae Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129654/
https://www.ncbi.nlm.nih.gov/pubmed/32893194
http://dx.doi.org/10.5009/gnl20151
_version_ 1783694343079460864
author Ahn, Young-Hwan
Lee, Heirim
Kim, Do Young
Lee, Hye Won
Yu, Su Jong
Cho, Young Youn
Jang, Jeong Won
Jang, Byoung Kuk
Kim, Chang Wook
Kim, Hee Yeon
Park, Hana
Cho, Hyo Jung
Park, Bumhee
Kim, Soon Sun
Cheong, Jae Youn
author_facet Ahn, Young-Hwan
Lee, Heirim
Kim, Do Young
Lee, Hye Won
Yu, Su Jong
Cho, Young Youn
Jang, Jeong Won
Jang, Byoung Kuk
Kim, Chang Wook
Kim, Hee Yeon
Park, Hana
Cho, Hyo Jung
Park, Bumhee
Kim, Soon Sun
Cheong, Jae Youn
author_sort Ahn, Young-Hwan
collection PubMed
description BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. RESULTS: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). CONCLUSIONS: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419)
format Online
Article
Text
id pubmed-8129654
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-81296542021-05-24 Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C Ahn, Young-Hwan Lee, Heirim Kim, Do Young Lee, Hye Won Yu, Su Jong Cho, Young Youn Jang, Jeong Won Jang, Byoung Kuk Kim, Chang Wook Kim, Hee Yeon Park, Hana Cho, Hyo Jung Park, Bumhee Kim, Soon Sun Cheong, Jae Youn Gut Liver Original Article BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. RESULTS: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). CONCLUSIONS: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419) Editorial Office of Gut and Liver 2021-05-15 2020-09-09 /pmc/articles/PMC8129654/ /pubmed/32893194 http://dx.doi.org/10.5009/gnl20151 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ahn, Young-Hwan
Lee, Heirim
Kim, Do Young
Lee, Hye Won
Yu, Su Jong
Cho, Young Youn
Jang, Jeong Won
Jang, Byoung Kuk
Kim, Chang Wook
Kim, Hee Yeon
Park, Hana
Cho, Hyo Jung
Park, Bumhee
Kim, Soon Sun
Cheong, Jae Youn
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title_full Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title_fullStr Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title_full_unstemmed Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title_short Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
title_sort independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis c
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129654/
https://www.ncbi.nlm.nih.gov/pubmed/32893194
http://dx.doi.org/10.5009/gnl20151
work_keys_str_mv AT ahnyounghwan independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT leeheirim independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT kimdoyoung independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT leehyewon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT yusujong independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT choyoungyoun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT jangjeongwon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT jangbyoungkuk independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT kimchangwook independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT kimheeyeon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT parkhana independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT chohyojung independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT parkbumhee independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT kimsoonsun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc
AT cheongjaeyoun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc